Abstract
We investigated the impact of COVID-19 restrictions on the duration of untreated psychosis (DUP). First-episode psychosis admissions (n=101) to STEP Clinic in Connecticut showed DUP reduction (p=.0015) in the pandemic, with the median reducing from 208 days during the pre-pandemic to 56 days in the early pandemic period and subsequently increasing to 154 days (p=.0281). Time from psychosis onset to anti-psychotic prescription decreased significantly in the pandemic (p=.0183), with the median falling from 117 to 35 days. This cohort study demonstrates an association between greater pandemic restrictions and marked DUP reduction and provides insights for future early detection efforts.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institutes of Health (R01MH103831) and the Gustavus and Louise Pfeiffer Research Foundation. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. This work was also funded by the State of Connecticut, Department of Mental Health and Addiction Services, but this publication does not express the views of the Department of Mental Health and Addition Services or the State of Connecticut. The views and opinions expressed are those of the authors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of Yale University gave ethical approval for this work (Protocol Number: 1310012846).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Relevance statement This work demonstrates a reduction in the duration of untreated psychosis (DUP) during times of stricter COVID-19 restrictions. A shorter DUP is associated with better clinical outcomes, therefore it is important for clinicians to understand the determinants of DUP. The delay reduction is predominantly on the community side of the pathway to specialist services, with a potential role of family members, providing insight for clinicians implementing early detection programmes. Exploring the impact of the pandemic on pathways to care is helpful for clinicians to understand the influence of environmental factors on psychiatric presentations, and to prepare for future events.
Declaration of Interest: none
Funding Statement: This work was supported by the National Institutes of Health (R01MH103831) and the Gustavus and Louise Pfeiffer Research Foundation. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. This work was also funded by the State of Connecticut, Department of Mental Health and Addiction Services, but this publication does not express the views of the Department of Mental Health and Addition Services or the State of Connecticut. The views and opinions expressed are those of the authors.
Transparency declaration: The manuscript is an honest, accurate, and transparent account of the study; no important aspects of the study have been omitted; any discrepancies from the study as planned have been explained.
Data availability: The data that support the findings of this study are available from the corresponding author, VS.
Trial registration: ClinicalTrials.gov NCT02069925.
nichollsmindlin{at}newcastle.ac.uk
Data Availability
All data produced in the present study are available upon reasonable request to the authors
